References
Lyman CA, Walsh TJ. Drugs 44: 9–35, 1992
Perfect JR, et al. Drug Safety 7: 323–363, 1992
Saag MS, et al. N Engl J Med 326: 83–89, 1992
Tucker RM, et al. Rev Infect Dis 12 (Suppl. 3): S380–S389, 1990
Sugar AM, Saunders C. Am J Med 85: 481–489, 1988
Robinson PA, et al. Rev Infect Dis 12: S349–S363, 1990
Kidd D, et al. Lancet 1: 1017, 1989
Sharkey PK, et al. Antimicrob Agents Chemother 35: 707–713, 1991
Restrepo A, et al. Arch Dermatol 122: 413–417, 1986
Tucker RM, et al. J Antimicrob Chemother 26: 561–566, 1990
Pont A, et al. Arch Intern Med 144: 2150–2153, 1984
Fromtling RA. Clin Microbiol Rev 1: 187–217, 1988
Graybill JR. Infect Dis Clin North Am 2: 805–825, 1988
Sung JP, et al. West J Med 126: 5–13, 1977
Deresinski SC, et al. Arch Intern Med 137: 1180–1185, 1977
Stevens DA. Am Rev Respir Dis 116: 801–806, 1977
Rights and permissions
About this article
Cite this article
Prevention and Management of Adverse Drug Reactions to Systemic Antifungals: Part 2. Drugs Ther. Perspect 1, 13–15 (1993). https://doi.org/10.2165/00042310-199301050-00006
Published:
Issue Date:
DOI: https://doi.org/10.2165/00042310-199301050-00006